Voltage-gated sodium (Na v ) channels are essential for the rapid upstroke of action potentials and the propagation of electrical signals in nerves and muscles.
INTRODUCTION
Voltage-gated sodium (Na v ) channels are essential for the rapid depolarization phase of action potential and play a key role in the electrical signaling in most excitable cells. Structurally, Na v channels are composed of one α subunit and one or more β subunits. The α subunit contains two functionally distinct structural entities, namely, the voltage-sensing domains (VSDs) and the ion-conducting pore domain (Catterall, 2012b (Catterall, , 2014 . The β subunits, which bind to α subunit covalently or non-covalently, modulate membrane trafficking, voltage dependence, and channel gating kinetics (Catterall, 2012b (Catterall, , 2014 . In mammals, Na v channels have nine known α members distributed in different excitable tissues. Specifically, Na v 1.1, Na v 1.2, Na v 1.3, and Na v 1.6 are the primary sodium channels in central nervous system (CNS), Na v 1.4 is primarily expressed in skeletal muscle, Na v 1.5 is mainly expressed in heart, and Na v 1.7, Na v 1.8, and Na v 1.9 are mainly distributed in peripheral nervous system (Plummer and Meisler, 1999; Goldin, 2001; Catterall et al., 2005) .
All α subunits share nearly identical structure topology-a canonical voltage-gated ion channel fold with four homologous repeats, each containing six transmembrane segments S1-S6. Specifically, S5-S6 segments form the pore domain that conducts selective sodium filtering, while S1-S4 segments constitute the voltage-sensing domain that controls voltage-dependent gating (Catterall, 2000) . The voltage sensors in the VSDs are featured by a number of positively charged amino acids (arginine or lysine) located at every third position in the S4 segment. Upon membrane depolarization, movements of these charged residues in the S4 segment are coupled to the opening of the pore domain and the subsequent influx of sodium ions across cell membrane. The pore domain is structurally organized with a four-fold pseudo-symmetry. The pore (P) loops, which are supported by the P1 helix (corresponding to the P helix in potassium channel) and P2 helix between S5 and S6 segments in each repeat, constitute the selectivity filter (SF) (Corry and Thomas, 2012) . Four amino acid residues (aspartate, glutamate, lysine, and alanine, DEKA, in repeats I, II, III, and IV, respectively) in the P loops are crucial for sodium selectivity. Mutating these residues to glutamates confers calcium selectivity, suggesting that the side chains of these amino acids are likely to interact directly with the sodium ions to determine ion selectivity (Heinemann et al., 1992; Sun et al., 1997) . Na v channels inactivate rapidly. A cluster of hydrophobic amino acids (isoleucine, phenylalanine, methionine, and threonine), namely the IFMT motif, located in the cytosolic regions of domain III and domain IV, are required for rapid inactivation. This is demonstrated by the fact that rapid inactivation could be achieved by titrating small peptides containing the IFMT motif (Vassilev et al., 1988; West et al., 1992) .
Sodium channelopathies are a group of diseases caused by defective Na v channels, either, in most cases, of congenital nature or acquired nature (Tables 1, 2 , 3, 4, 5, 6, 7, 8, 9, 10) (George, 2005; Catterall, 2012a; Kim, 2014) . For example, Na v 1.1 is primarily expressed in the soma of neuronal cells in the CNS, and mutations of Na v 1.1 cause GEFS+2 (generalized epilepsy with febrile seizures plus 2) (Catterall et al., 2010) . Moreover, mutations of Na v 1.1 are also the main causes of EIEE6 (epileptic encephalopathy, early infantile, 6) and ICEGTC (intractable childhood epilepsy with generalized tonic-clonic seizures) (Escayg and Goldin, 2010) . Na v 1.5 is the major sodium channel expressed in heart. Na v 1.5 mutations may lead to various cardiac diseases such as LQT3 (long QT syndrome 3), BRGDA1 (Brugada syndrome 1), and SSS1 (sick sinus syndrome 1) (Olson et al., 2005; Song and Shou, 2012; Veerman et al., 2015) . Na v 1.7 is preferentially expressed in the sympathetic neurons, olfactory epithelium, and dorsal root ganglion sensory neurons, and plays a cardinal role in pain transmission (Djouhri et al., 2003; Dib-Hajj et al., 2013) . Gain-of-function mutations of Na v 1.7 are implicated in two distinct paroxysmal pain syndromes-IEM (primary erythermalgia) and PEPD (paroxysmal extreme pain disorder), while loss-of-function mutations of Na v 1.7 inflict people with CIP (indifference to pain, congenital, autosomal recessive) (Lampert et al., 2010; Dib-Hajj et al., 2013) . In all, Na v channel mutations play a central role in the pathophysiology of sodium channelopathies. Pharmacologic modulation of Na v channels may thereby represent a viable therapeutic approach for the treatment of many neurological disorders such as epilepsy, arrhythmia, and pain. Despite significant advancement in the understanding of Na v channel functions and their relevance to diseases, structural characterization of mammalian Na v channels at atomic level has been challenging, partly due to the substantial technical hurdles in producing mammalian Na v channel proteins in sufficient amount with acceptable purity. The two published bacterial Na v channel crystal structures, Na v Ab (Payandeh et al., 2011) and Na v Rh , in their full-length have greatly improved our understanding of how those channels conduct and select sodium ions on a structural basis. This is further enhanced by the recently published cryo-electron microscopy (cryo-EM) structure of the rabbit voltage-gated calcium (Ca v ) channel Ca v 1.1 (Wu et al., 2015; Wu et al., 2016) , which, given the significant similarities between Ca v and Na v channels, provides an excellent base model for studying the structure and function of the mammalian Na v channels in lieu of the elusive Na v channel structure (Wu et al., 2015; Wu et al., 2016) . In this Resource article, we have built a structure model of the human sodium channel Na v 1.7 based on the Ca v 1.1 cryo-EM structure (PDB code: 5GJV). Disease-related mutations of various Na v channels are systematically mapped onto this Na v 1.7 structural model. As expected, most mutations are located in the VSDs and the pore domain, which corroborate the functional disturbance associated with the various conditions. The human Na v 1.7 structure model may also provide a useful tool for the structure-based design of drugs that are able to therapeutically target the Na v channels.
STRUCTURE MODEL OF HUMAN SODIUM CHANNEL NA V 1.7
Homology models of the mammalian Na v channels have been previously constructed based on the crystal structures of the eukaryotic potassium channels or the prokaryotic sodium channels (Tikhonov and Zhorov, 2012; Yang et al., 2012) . However, the relevance of such models has been in question, since the eukaryotic sodium channels are known to be heterotetrameric while the prokaryotic sodium channels and the potassium channels are of homotetrameric nature.
We sought to build a homology-based structural model for human Na v 1.7 because of the tremendous interest in drug development targeting this channel. The sequence identity and similarity between human Na v 1.7 and rabbit Ca v 1.1 are 21 and 35%, respectively (Please refer to the online Supplementary Fig. 2 of Wu et al., 2016) . Importantly, the key amino acids within the VSDs and the pore domains are highly conserved (Wu et al., 2015; Wu et al., 2016) . The cryo-EM structure of rabbit Ca v 1.1 was then used as the template for homology modeling of human Na v 1.7. The primary sequence of human Na v 1.7 was aligned with rabbit Assessment of disease-related mutations in sodium channels Ca v 1.1 in MOE with manual adjustment when necessary. The structure model of human Na v 1.7 was created with the Homology Model module in MOE using the GB/VI scoring function with AMBER12:EHT force field (MOE, 2016). The human Na v 1.7 model structure resembles the structure of rCa v 1.1 in general (Fig. 1A) . However, the model exhibits pronounced differences from the calcium channel and bacterial sodium channels particularly in selectivity filter. The SF of Na v 1.7 consists of four different amino acid residues DEKA (Fig. 1B) . In contrast, the Ca v 1.1 SF is constituted by four repeated essential glutamic acids, EEEE, while Na v Ab and Na v Rh contain TLESWS or TLSSWE in each protomer, respectively. This human Na v 1.7 structure model represents the first one-chain sodium channel model with asymmetric repeats and is expected to shed new light on the mammalian sodium channel functions.
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MAPPING OF DISEASE-RELEVANT MUTATIONS ONTO THE NA V 1.7 STRUCTURE MODEL
Human Na v 1.7 sodium channel is preferentially expressed in the sensory neurons of dorsal root ganglia and sympathetic ganglia neurons, particularly within the nociceptors, which is essential for perceiving pain (Djouhri et al., 2003; Dib-Hajj et al., 2013) . To date, about 60 mutations of Na v 1.7 have been found to cause human pain syndromes including IEM, PEPD, CIP, SFN (small fiber neuropathy), DS (Dravet syndrome), and FEB (febrile seizure) ( Fig. 2 and Table 1 ). We mapped all the reported Na v 1.7 mutations onto this Na v 1.7 structure model (Fig. 2) . Nineteen out of 22 IEM mutations are located in the highly conserved regions of VSDs and the pore domain except for the Q10R, P610T, and G616R mutations (Fig. 2) . Electrophysiology study showed that IEM mutations cause a prominent shift of the activation voltage toward a more negative region or delay deactivation, which results in neuron hyperexcitability (Choi et al., 2006; Lampert et al., 2006; Choi et al., 2009; Lampert et al., 2010) . For example, mutation of A1643 within the S5 segment of domain IV to glycine (A1643G) generates a significant hyperpolarizing shift (Yang et al., 2016) . Our structural analysis shows that only two IEM mutations F216S and L834R are located in the S4 positively charged segment that is directly responsible for transmembrane voltage sensing and channel activation. How other IEM mutations influence voltage sensing and channel functions is yet to be elucidated.
The PEPD mutations are mostly characterized (nine out of 11) within the S4 segment, S4-S5 linker region, and the cytosolic regions of domain III and domain IV of Na v 1.7 except for R185H and R1007C ( Fig. 2A and Table 1) . Specifically, I1472T, F1473V, and T1475I are within the IFMT motif ( Fig. 2A) , indicating that they may disturb channel inactivation. Indeed, IFMT mutations usually impair fast inactivation with consequently persistent currents (Fertleman et al., 2006) . The V1309D, V1309F, and V1310F mutations are located in the S4-S5 linker region of domain III and they have been shown to cause moderate destabilization of fast inactivation . The G1618R mutation, located within the S4 segment of domain IV, impairs inactivation and retains a persistent current compared to the wildtype (WT) channel (Choi et al., 2011) , while another domain IV S4 segment mutation, L1623P, significantly increases ramp current and shortens recovery time from inactivation (Suter et al., 2015) . Moreover, electrophysiology study showed that M1638K mutation (within the S5 segment of domain IV) generates faster recovery from inactivation than the WT channel, producing greater currents and reducing the threshold with increased number of action potentials (Fertleman et al., 2006; Dib-Hajj et al., 2008) . Another PEPD mutation, A1643E, also located in the S5 segment of domain IV, impedes channel full inactivation, which results in persistent inward currents .
The CIP patients, characterized by lack of nociceptive perception, are mostly inflicted by Na v 1.7 nonsense mutations, which result in premature protein truncations and inability to produce functional sodium channels. Only three mutations of Na v 1.7, namely R907Q, A1247E, and W1786R, have been reported to be associated with CIP ( Fig. 2 and Table 1 ). Diseases such as DS, SFN, and FEB are also known to be caused by Na v 1.7 mutations (Fig. 2 and Table 1 ). For example, all eight SFN mutations have been characterized. Specifically, I228M, I731K, I750V, and M1543I mutations impair slow inactivation, D623N impedes slow and fast inactivation, while R185H, M943L, and V1002L mutations enhance resurgent currents (Faber et al., 2012a) . Assessment of disease-related mutations in sodium channels On the other hand, Na v 1.7 mutations that are associated with DS (nine mutations) and FEB (six mutations) have not been well characterized.
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MAPPING OF OTHER HUMAN SODIUM CHANNEL DISEASE-RELATED MUTATIONS ONTO THE NA V 1.7 STRUCTURE MODEL
Members of the human Na v channel family share high sequence similarity and mutations of these Na v channels are known to cause a vast variety of channelopathies. In order to better understand the role of those mutations in disturbing normal channel functions on a structural level, we mapped the disease-related mutations of other human Na v channels onto the Na v 1.7 structure model based on the sequence alignment reported in Wu et al., 2016 (Fig. 3) . Among all the nine Na v channels, Na v 1.1 and Na v 1.5 have the largest numbers of reported mutations (more than 400 each) (Fig. 3A and 3E ), while Na v 1.3, Na v 1.8, and Na v 1.9 have the least numbers (less than 10 each) (Fig. 3C,  3H , and 3I). Notably, mutations in Na v 1.1, Na v 1.2, Na v 1.3, and Na v 1.6 mainly cause epilepsies; those in Na v 1.4 are related to myopathies; in Na v 1.5 result in cardiac channelopathies; and in Na v 1.7, Na v 1.8, and Na v 1.9 are associated with pain-related diseases ( Fig. 3 and Tables 1,  2 , 3, 4, 5, 6, 7, 8, 9, 10) . Mapping of all Na v channel mutations onto the Na v 1.7 structure model revealed that more than 80% of mutations are located in the VSDs and pore domains ( Fig. 4A and 4B) . Notably, disease-causing mutations are somewhat equally distributed in all four Na v channel domains, which account for more than 20 sodium channelopathies (Fig. 4C) . Furthermore, mutations are also distributed in various regions of the pore domains, suggesting that they may disturb Na v channel functions by altering sodium ion selectivity and conductivity (Fig. 4D) . Na v 1.2 mutations are largely associated with various epilepsy diseases, including BFIS3 (seizures, benign familial infantile 3), EIEE11 (epileptic encephalopathy, early infantile, 11), and DS ( Fig. 3B and Table 3 ). More than 30 Na v 1.2 mutations have been discovered and some of them are now functionally characterized. Interestingly, electrophysiological studies showed that Na v 1.2 mutations can either be loss-offunction (R1319Q and L1330F) or gain-of-function (M252V, PFHB1A: Progressive familial heart block 1A; LQT3: Long QT syndrome 3; BRGDA1: Brugada syndrome 1; SSS1: Sick sinus syndrome 1; VF1: Familial paroxysmal ventricular fibrillation 1; SIDS: Sudden infant death syndrome; ATRST1: Atrial standstill 1; CMD1E: Cardiomyopathy, dilated 1E; ATFB10: Atrial fibrillation, familial, 10; MEPPC: Multifocal ectopic Purkinje-related premature contraction. V261M, L1563V, and Y1579C) (Misra et al., 2008; Liao et al., 2010; Lauxmann et al., 2013) . It is noted that BFIS3 mutations in Na v 1.2 create less pronounced changes in the activation and inactivation potentials than the EIEE11 mutations (Shi et al., 2012) . Only six missense mutations of Na v 1.3 have so far been identified in patients with cryptogenic partial epilepsy ( Fig. 3C and Table 4 ). Five of them, namely K354Q, R357Q, D815N, E1160K, and M1372V, have been characterized, all of which are gain-of-function mutations, consistent with the neuronal hyperexcitability phenotype (Estacion et al., 2010; Vanoye et al., 2014) . Na v 1.4 is essential for controlling the muscle action potential and consequently crucial for skeletal muscle contraction. Mutations of Na v 1.4 are related with various neuromuscular disorders including PMC (paramyotonia congenita of von Eulenburg), HOKPP2 (periodic paralysis hypokalemic 2), HYPP (periodic paralysis hyperkalemic), NKPP (periodic paralysis normokalemic), MYOSCN4A (myotonia SCN4A-related), and CMS16 (myasthenic syndrome, congenital, 16) ( Fig. 3D and Table 5 ). Different disease-causing mutations alter the Na v 1.4 channel function through distinct mechanisms. For example, CMS16 mutations R104H, P382T, and C1209F completely abolish the Na v 1.4 channel's ability to conduct sodium ion, while other mutations such as M203K, R225W, and D1069N cause reduced action potential amplitude, leading to impaired channel function (Zaharieva et al., 2016) . Compared to the WT channel, a CMS16 voltage sensor mutant R1457H requires longer hyperpolarization to recover which results in increased fast inactivation (Arnold et al., 2015) . On the other hand, a HOKPP2 mutation R1135H (the third arginine in the domain III voltage sensor) exhibits increased depolarization, suggesting that R1135H mutation be gain-of-function (Groome et al., 2014) . A MYOSCN4A mutation I582V shows a hyperpolarizing shift of 6 mV, indicating the nature of this mutation be also gain-of-function (Corrochano et al., 2014) .
Na v 1.6 is one of the sodium channels expressed in human brain and mutations of Na v 1.6 cause EIEE13 (epileptic encephalopathy, early infantile, 13) ( Fig. 3F and Table 7 ). More than 40 Na v 1.6 mutations have been discovered since 2012 ( Fig. 3F and Table 7) , and seven of them have been studied in the functional assays. Specifically, five Na v 1.6 mutations, namely T767I, N984K, T1716I, N1768D, and R1872W/R1872Q/R1872L, are characterized as gainof-function, which cause hyperpolarizing shift of inactivation voltage or increased persistent current (Veeramah et al., 2012; Estacion et al., 2014; Wagnon et al., 2016) , while the Assessment of disease-related mutations in sodium channels RESOURCE other two mutations, R223G and G1451S, are loss-of-function (de Kovel et al., 2014; Blanchard et al., 2015) . Five Na v 1.8 mutations are associated with SFN, a condition that is clinically characterized by autonomic dysfunction and burning pain in the distal extremities ( Fig. 3H and Table 8 ). Electrophysiology study has shown that Na v 1.8 mutations, specifically L554P, A1304T, G1662S, and I1706V, accelerate inactivation recovery and enhance activation, which result in hyperexcitability (Faber et al., 2012b; Huang et al., 2013; Han et al., 2014) . However, another SFN Na v 1.8 mutation M650K causes reduced excitability of C fibers (Kist et al., 2016) . FEPS3 (episodic pain syndrome, familial, 3) and HSAN7 (neuropathy, hereditary sensory and autonomic, 7) are thought to be caused by the nine missense gain-of-function mutations of Na v 1.9 ( Fig. 3I and Table 9 ). Specifically, compared to the WT channel, R225C and A808G mutations induce hyperexcitability of the DRG neurons (Zhang et al., 2013) , G699R enhances activation (Han et al., 2015) , L811P significantly increases current density (Leipold et al., 2013) , L1158P enhances spontaneous firing (Huang et al., 2014) , and V1184A alters the channel voltage dependence that results in channel opening in response to hyperpolarized potentials (Leipold et al., 2015) .
DISEASE-RELATED MUTATIONS IN SODIUM
CHANNELS NA V 1.1 AND NA V 1.5
Mutations of Na v 1.1 are associated with several neurological disorders including GEFS+2, EIEE6, ICEGTC, FHM3 (migraine, familial hemiplegic, 3), and FEB3A (febrile seizures, familial, 3A) ( Table 2 and Table 10 ). More than 400 mutations of Na v 1.1 have been identified, approximately 10% account for GEFS+2 while 80% for EIEE6 (Fig. 5A and Table 2 ). By mapping the Na v 1.1-related mutations to the Na v 1.7 structure model, we identified that most mutations are located in the VSDs and the pore domain (Fig. 5A ). For example, mutations of the four positively charged residues, R1639G, R1642S, R1645Q, and R1648C, are present in the domain IV S4 segment ( Table 2 ), suggesting that these EIEE6 mutations may alter the voltage sensing behavior of the channel. In addition, it is noteworthy that Na v 1.1 mutations can be either loss-of-function or gain-of-function (Catterall et al., 2010; Escayg and Goldin, 2010) . For example, two GEFS+2 mutations W1204R and R1648H increase the level of persistent current through gain-of-function (Lossin et al., 2002) , while the loss-of-function M145T mutation in FEB3A decreases 60% of the current density (Mantegazza et al., 2005) . Na v 1.5 is the primary sodium channel in the heart and is essential for the cardiac action potential initiation. More than 400 Na v 1.5 mutations have been discovered and they are implicated in a wide variety of cardiac diseases-including PFHB1A (progressive familial heart block 1A), LQT3, BRGDA1, SSS1, VF1 (familial paroxysmal ventricular fibrillation 1), SIDS (sudden infant death syndrome), ATRST1 (atrial standstill 1), CMD1E (cardiomyopathy, dilated 1E), ATFB10 (atrial fibrillation, familial, 10), and MEPPC (multifocal ectopic Purkinje-related premature contractions) ( Fig. 5B and Table 6 ). By mapping all the Na v 1.5 mutations onto the Na v 1.7 structure model, it shows that most mutations are located in the transmembrane regions of the IEM   PEPD   CIP   Q10R  I136V  S211P  F216S  I234T   S241T  L245V  N395K  V400M E406K   P610T  G616R  L834R  I859T  G867D   F1460V  A1643E  A1643G  A1643T   L869H   L869F  A874P  V883G  Q886E P1319L   1  2  3  4  5   6  7  8  9  1 0   11  12  13  14  15   16  17   21  22   18  19  20   R907Q  W1786R  A1247E   1  2  3   R185H  R1007C V1309F  V1309D V1310F I1472T   F1473V   A1643E   T1475I  G1618R L1623P M1638K   1  2  3  4  5   6  7  8  9  1 0   11   E519K  K666R  I695M  C710Y I750V  L1134F  E1171Q  L1278V  I228M  1  2  3  4  5  6  7  8  9   R185H  I228M  D623N  I731K  I750V  M943L  V1002L  M1543I  1  2  3  4  5  6  7  8   I62V  S490N  P149Q  N641Y K666R  I750V  1  2  3  4  5 
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Weiyun Huang et al. channel, suggesting that these mutations might disturb voltage sensing or sodium conduction (Fig. 5B) . Furthermore, about 50% of the Na v 1.5 mutations account for BRGDA1, while 30% for LQT3. Similar to the case of Na v 1.1, mutations in Na v 1.5 can be either loss-of-function or gain-offunction. For example, loss-of-function mutations are associated with BRGDA1, CMD1E, SSS1, and ATFB10 (Tan et al., 2001; Smits et al., 2005; Makiyama et al., 2008; Laurent et al., 2012) , while gain-of-function mutations of Na v 1.5 are responsible for LQT3 (Remme et al., 2006) , CMD1E, and ATFB10 (Olson et al., 2005) , and most recently MEPPC (Swan et al., 2014) .
CONCLUDING REMARKS
The Na v family of sodium channels are important drug targets for the pharmaceutical industry. However, no atomic structure of any mammalian Na v channels is currently available, preventing the establishment of an in-depth structure-function relationship for this important group of sodium channels and application of structure-based approach to rationally design compounds that are able to modulate the functions of those Na v channels in a disease relevant manner. Using the recently published cryo-EM structure of a rabbit Ca v channel Ca v 1.1, we established an atomic level heterotetrameric structure model for the human Na v channel Na v 1.7. Disease-related mutations of Na v 1.7 and other members of the Na v family, which are largely responsible for many neurological disorders like epilepsies, pains, and myopathies, are mapped onto the structure model. Taken together the available functional data, we attempted to establish a rudimentary structure-function relationship for human Na v 1.7 and other members of the Na v channel family. It is noticeable that sodium channelopathies can be attributed to both loss-of-function and gain-of-function mutations.
Na v 1.9 Na v 1.8 Na v 1.7 Na v 1.6 Na v 1.5 Na v 1.4 Na v 1.3 Na v 1.2 Na v 1.1 Figure 3 . Mapping of Na v channel disease-related mutations onto the Na v 1.7 structure model. The Na v 1.7 channel is shown in cartoon from the intra-membrane view. The Cα atoms of the disease-related amino acids are shown in spheres. Mapped mutations from nine Na v sodium channels to the Na v 1.7 structure model are differentiated by distinct colors, Na v 1.1 (A, blue), Na v 1.2 (B, cyan), Na v 1.3 (C, magenta), Na v 1.4 (D, purple blue), Na v 1.5 (E, pale cyan), Na v 1.6 (F, orange), Na v 1.7 (G, red), Na v 1.8 (H, green), and Na v 1.9 (I, salmon).
However, we must realize that the current Na v 1.7 structural model has its limitation and the atomic resolution mammalian Na v channel structure is urgently needed. In recent years, cryo-EM technology is becoming a mainstream technology for structural biology, which is able to potentially overcome the significant technical hurdles in producing challenging proteins such as mammalian Na v channels in sufficient quality and the necessity of crystallization for structural elucidation. Detailed mechanisms of how the Na v channels sense voltage changes and conduct sodium ions can only be answered when such atomic resolution structures become available. We hope the Na v 1.7 structure model presented here is a temporary surrogate to help understand the Na v channel functions, particularly those relevant to the various neurological diseases, at atomic level, and contributes to the structurebased rational design of the next generation Na v channel modulators. Nav1.9 Nav1.8 Nav1.7 Nav1.6 Nav1.5 Nav1.4 Nav1.3 Nav1.2 Nav1.1 D C B A Figure 4 . Mutations that cause sodium channelopathies are plotted on the Na v 1.7 sodium channel model. (A) The amino acid residues related with sodium channelopathies are mapped on the Na v 1.7 structure model. All mutated residues are shown in spheres and colored for Na v 1.1 (blue), Na v 1.2 (cyan), Na v 1.3 (magenta), Na v 1.4 (purple blue), Na v 1.5 (pale cyan), Na v 1.6 (orange), Na v 1.7 (red), Na v 1.8 (green), and Na v 1.9 (salmon). (B) The distribution of sodium channelopathy-related mutations on the transmembrane regions of the Na v 1.7 structure model. Mutations of the VSDs and the pore domain are shown from the intra-membrane and intracellular views. (C) The mutation distributions for the four domains. S1-S6 segments are shown in cylindrical helices. (D) Mapping mutations to the pore domain in four different views. 
